The Circulatory System: Structure and Function

The circulatory system—also called the cardiovascular system—is composed of the heart, arteries, veins, capillaries, and the blood itself. Its primary role is to deliver oxygen and nutrients to every cell, remove carbon dioxide and metabolic waste, regulate body temperature, and distribute hormones and immune cells. The heart acts as a powerful dual pump: the right side receives deoxygenated blood from the body and sends it to the lungs for oxygenation, while the left side receives oxygenated blood from the lungs and propels it out to all tissues. This continuous loop is driven by rhythmic contractions controlled by the sinoatrial node, the heart’s natural pacemaker.

Blood Vessels: The Body’s Highways

Three main types of blood vessels form the transport network:

  • Arteries – thick-walled vessels built to carry blood away from the heart under high pressure. The aorta, the largest artery, branches into smaller arteries and arterioles. Their muscular walls help regulate blood pressure and flow.
  • Veins – thinner-walled vessels that return deoxygenated blood to the heart. Many veins contain one-way valves that prevent backflow, especially in the legs where blood must travel against gravity. Venules are the smallest veins that collect blood from capillaries.
  • Capillaries – microscopic vessels with walls just one cell thick. They form networks (capillary beds) where gases, nutrients, and wastes are exchanged between blood and interstitial fluid.

The maintenance of this network is critical: any disruption in blood flow—from a clot, a plaque rupture, or hemorrhage—can quickly become life-threatening. Transfusion medicine exists to restore blood volume and oxygen-carrying capacity when the body’s own circulatory system cannot keep up, whether from trauma, surgery, or chronic disease.

The Role of Blood

Blood is a specialized connective tissue that accounts for about 7% of body weight. It is composed of:

  • Red blood cells (erythrocytes) – carry oxygen via hemoglobin, a protein that binds oxygen in the lungs and releases it in tissues. They have no nucleus and live about 120 days.
  • White blood cells (leukocytes) – fight infection and support immune function. Five types exist, each with distinct roles (neutrophils, lymphocytes, monocytes, eosinophils, basophils).
  • Platelets (thrombocytes) – small cell fragments essential for clotting and wound healing.
  • Plasma – the liquid matrix, about 92% water, that transports nutrients, hormones, waste products, and clotting factors. Plasma also contains proteins such as albumin and immunoglobulins.

In transfusions, the focus is often on red blood cells, but whole blood, plasma, and platelets can each be transfused separately depending on clinical need. For example, plasma is used to correct coagulopathies, while platelets are given to patients with low counts or bleeding risk.

Blood Types: The ABO and Rh Systems

Blood types are determined by the presence or absence of specific antigens—molecules that can trigger an immune response—on the surface of red blood cells. The two most clinically important systems are the ABO system and the Rh system. Understanding these is the cornerstone of transfusion safety, and every healthcare professional must grasp the principles to prevent life-threatening reactions.

The ABO Blood Group System

Discovered by Karl Landsteiner in 1901, the ABO system classifies blood into four main types based on two antigens, A and B. The presence or absence of these antigens is inherited from our parents, and the immune system naturally produces antibodies against the antigens we lack:

  • Type A – red cells have A antigens; plasma contains anti-B antibodies.
  • Type B – red cells have B antigens; plasma contains anti-A antibodies.
  • Type AB – red cells have both A and B antigens; plasma has no anti-A or anti-B antibodies.
  • Type O – red cells have neither A nor B antigens; plasma contains both anti-A and anti-B antibodies.

These antibodies are formed early in life (around 3–6 months) without prior exposure to foreign red cells, likely in response to bacteria expressing similar antigens. When a person receives blood containing an antigen that their immune system recognizes as foreign, a rapid antibody-mediated attack occurs. For example, if a person with type A blood receives type B blood, the anti-B antibodies in the recipient’s plasma will bind to the donor B antigens, causing agglutination (clumping) and hemolysis (red cell destruction), which can lead to renal failure, shock, and death.

ABO frequencies vary globally. In the United States, type O is most common (about 45%), followed by A (40%), B (11%), and AB (4%). However, these distributions differ by ancestry—type B is more prevalent in Asian populations, making blood type diversity an important consideration for transfusion services.

The Rh Factor

The Rh factor is another antigen system, of which the D antigen is the most clinically important. People who have the D antigen on their red cells are Rh-positive (Rh+); those who lack it are Rh-negative (Rh−). Unlike ABO antibodies, anti-Rh antibodies are not naturally present. Instead, they form only after the immune system is exposed to Rh-positive blood—for instance, when an Rh-negative person receives Rh-positive blood via transfusion, or when an Rh-negative mother carries an Rh-positive baby and fetal red cells enter her circulation. This sensitization can lead to severe hemolytic reactions in future transfusions or to hemolytic disease of the newborn (HDN) in subsequent pregnancies, where maternal anti-D antibodies cross the placenta and attack fetal red cells. HDN can cause neonatal jaundice, anemia, brain damage, or death, but it is now preventable with Rho(D) immune globulin (RhoGAM), given to Rh-negative mothers during and after pregnancy.

Blood Compatibility and Transfusion Safety

Compatibility is determined by matching donor antigens to recipient antibodies. The goal is to prevent the recipient’s immune system from attacking the transfused red cells. A mismatch can cause immediate agglutination and hemolysis, leading to acute kidney injury, disseminated intravascular coagulation, and death within minutes. Therefore, careful pre-transfusion testing is mandatory.

The Universal Donor and Universal Recipient

Because type O red cells lack A and B antigens, they can be given to any patient—making O-negative blood the “universal donor” for red blood cell transfusions. Conversely, type AB individuals have no anti-A or anti-B antibodies in their plasma, so they can receive any ABO blood type—hence “universal recipient” for red cells. However, these are simplifications useful in emergencies. In practice, full crossmatching is still performed whenever possible, and even universal donor blood may carry other antigens that could cause reactions in certain patients. For plasma transfusions, the compatibility rules reverse: type AB plasma can be given to all, while type O plasma can only go to type O recipients because it contains both anti-A and anti-B antibodies.

Compatibility Chart (Simplified)

Below is a basic guide for red blood cell compatibility. The donor type is listed on the left, and compatible recipient types are on the right:

  • O− → All types (universal donor)
  • O+ → O+, A+, B+, AB+
  • A− → A−, A+, AB−, AB+
  • A+ → A+, AB+
  • B− → B−, B+, AB−, AB+
  • B+ → B+, AB+
  • AB− → AB−, AB+
  • AB+ → AB+ (universal recipient for red cells)

For plasma transfusions, the compatibility rules reverse: type AB plasma can be given to all, while type O plasma can only go to type O recipients.

Why Rh Matters in Compatibility

Rh compatibility is especially critical for women of childbearing age. An Rh-negative woman carrying an Rh-positive baby may develop anti-D antibodies. If she later receives Rh-positive blood, a severe reaction can occur. The same antibodies can also cross the placenta in a subsequent pregnancy, attacking the baby’s red cells—a condition preventable with Rho(D) immune globulin (RhoGAM). In transfusion settings, Rh-negative patients should ideally receive Rh-negative blood, though in emergencies, Rh-positive blood may be given to Rh-negative males or postmenopausal females if Rh-negative units are unavailable, but this carries the risk of sensitization.

Transfusion Safety Protocols: From Donation to Infusion

Ensuring that the right blood reaches the right patient involves a multi-step process of testing, labeling, and verification. Health organizations worldwide follow stringent guidelines established by bodies such as the AABB (formerly American Association of Blood Banks) and the U.S. Food and Drug Administration.

Donor Screening and Blood Collection

Potential donors are screened for risk factors of infectious diseases and may be deferred based on travel, medications, or health conditions. At donation, blood is collected into sterile bags containing anticoagulant preservatives and tested for:

  • Blood type (ABO and Rh).
  • Infectious agents such as HIV, hepatitis B and C, syphilis, West Nile virus, and emerging pathogens.
  • Irregular antibodies that could cause reactions in recipients.

Donated blood components are then separated: red cells, platelets, plasma, and sometimes cryoprecipitate. Each component has a specific shelf life—red cells can be stored for up to 42 days under refrigeration, while platelets must be stored at room temperature and are usable for only 5–7 days, making inventory management a constant challenge.

Crossmatching: The Final Check

Before transfusion, a sample of the recipient’s blood is mixed with donor blood in a laboratory test called crossmatching. This tests for compatibility at the antibody-antigen level. A “major crossmatch” mixes recipient plasma with donor red cells to detect antibodies against donor antigens. A “minor crossmatch” mixes donor plasma with recipient red cells (though this is rarely needed today because donor plasma is usually removed or diluted). If any agglutination or hemolysis occurs, the units are considered incompatible and rejected. Modern immunohematology labs also perform antibody screening and identification to detect unexpected alloantibodies that might cause delayed reactions.

Labeling and Administration

Blood units are labeled with a unique identifier—often a barcode—to prevent mix-ups. Before transfusion, two healthcare workers must verify the patient’s identity against the blood product at the bedside, a safety practice known as the “two-person check.” This final check includes confirming the patient’s name, date of birth, hospital number, blood type, and the unit’s identifying number. Transfusions are started slowly for 15 to 30 minutes to monitor for acute reactions, with vital signs recorded regularly. Any symptom—chills, fever, back pain, dyspnea, or hypotension—should prompt immediate cessation of the transfusion and a thorough investigation.

Beyond ABO and Rh: Other Blood Group Systems

While ABO and Rh are the most important, over 30 other red blood cell antigen systems exist, including Kell, Duffy, Kidd, and MNS. Some of these can also cause transfusion reactions, though they are less common. For example, anti-Kell antibodies can cause hemolytic disease of the newborn and are an important cause of delayed hemolytic transfusion reactions. For patients who require long-term transfusions—such as those with sickle cell disease, thalassemia, or myelodysplastic syndromes—matching for these additional antigens is often performed to avoid alloimmunization (the development of antibodies against donor blood). Alloimmunization can lead to difficulties in finding compatible blood in the future and can shorten the survival of transfused red cells.

Rare Blood Types and the Global Need

A small percentage of people have very rare blood types—those missing high-frequency antigens found in most of the population. These individuals may need to rely on international rare donor registries when they require transfusion. The American Red Cross and other organizations maintain such databases to ensure blood is available for everyone, regardless of how uncommon their type may be. The International Society of Blood Transfusion maintains the International Rare Donor Panel, which coordinates the shipment of rare blood across borders. During acute shortages, such as after mass casualty events, the ability to quickly identify and mobilize these rare units can be lifesaving.

Transfusion Reactions and How to Prevent Them

Despite rigorous testing, transfusion reactions can still occur. They may be acute (within 24 hours) or delayed (days to weeks). Common types include:

  • Hemolytic reaction – ABO incompatibility causing destruction of donor cells; can be fatal. Symptoms include fever, chills, back pain, dark urine, and hypotension.
  • Febrile non-hemolytic reaction – fever due to antibodies against donor white cells or cytokines released during storage. This is reduced with leukoreduction (filtering out white blood cells), which is now standard for many blood products.
  • Allergic reaction – hives, itching, sometimes anaphylaxis (often due to plasma proteins). Mild urticaria can be treated with antihistamines; severe anaphylaxis requires immediate epinephrine and cessation of transfusion.
  • Transfusion-associated circulatory overload (TACO) – especially in patients with heart failure or renal impairment. Prevention includes using slower infusion rates and diuretics.
  • Transfusion-related acute lung injury (TRALI) – rare but severe respiratory distress caused by donor antibodies reacting with recipient white blood cells. TRALI is now the leading cause of transfusion-related death in the United States, but its incidence is decreasing thanks to donor screening policies (e.g., excluding donors with a history of multiple pregnancies).

The key to prevention lies in proper pre-transfusion testing, adherence to protocols, and immediate recognition of symptoms. Any sign of reaction should prompt the transfusion to be stopped and the blood unit returned for investigation. A thorough workup includes checking for hemolysis, repeating blood type and crossmatch, and culturing the blood unit if bacterial contamination is suspected.

The Future of Transfusion Medicine

Research continues to make transfusions safer and more effective. Advances include:

  • Genotyping of blood groups – using DNA tests to determine a patient’s exact red cell antigen profile, allowing for precise matching beyond serologic methods. This is particularly valuable for patients with complex antibody profiles.
  • Pathogen reduction technology – treating blood components with light (e.g., ultraviolet light) and chemicals (e.g., amotosalen) to inactivate bacteria, viruses, and parasites. This could reduce the risk of emerging pathogens and enhance safety.
  • Artificial blood substitutes – oxygen-carrying solutions made from modified hemoglobin or perfluorocarbons. While none are yet approved for routine clinical use in the United States, promising candidates are in clinical trials and could address supply shortages, especially in trauma settings.
  • Blood from stem cells – scientists are exploring ways to generate red blood cells in the lab from induced pluripotent stem cells or hematopoietic stem cells. This could create a limitless supply of O-negative blood, particularly valuable for rare blood types.

For now, the foundation of transfusion safety remains the careful determination of blood type and compatibility, a system that has saved millions of lives since Landsteiner’s discovery.

The circulatory system and blood typing are inseparable in clinical practice. A thorough understanding of how the heart and vessels function, alongside the antigen-antibody dynamics that define blood groups, empowers healthcare providers to transfuse with confidence. Whether in trauma, surgery, or chronic disease management, compatibility testing is the gatekeeper that ensures the gift of blood does not become a threat. By respecting the science behind blood types and adhering to strict safety protocols, the medical community continues to uphold the highest standard of care—turning a routine transfusion into a life-saving act.

For more information on blood donation and transfusion guidelines, visit the World Health Organization’s blood transfusion page or the National Heart, Lung, and Blood Institute.